397 related articles for article (PubMed ID: 29356634)
1. Radiotheranostics in Cancer Diagnosis and Management.
Jadvar H; Chen X; Cai W; Mahmood U
Radiology; 2018 Feb; 286(2):388-400. PubMed ID: 29356634
[TBL] [Abstract][Full Text] [Related]
2. Advances in Radioligand Theranostics in Oncology.
Lawal IO; Abubakar SO; Ndlovu H; Mokoala KMG; More SS; Sathekge MM
Mol Diagn Ther; 2024 May; 28(3):265-289. PubMed ID: 38555542
[TBL] [Abstract][Full Text] [Related]
3. PSMA-targeted radiotheranostics in modern nuclear medicine: then, now, and what of the future?
Sallam M; Nguyen NT; Sainsbury F; Kimizuka N; Muyldermans S; Benešová-Schäfer M
Theranostics; 2024; 14(8):3043-3079. PubMed ID: 38855174
[TBL] [Abstract][Full Text] [Related]
4. Radiotheranostics - Precision Medicine in Nuclear Medicine and Molecular Imaging.
Duan H; Iagaru A; Aparici CM
Nanotheranostics; 2022; 6(1):103-117. PubMed ID: 34976584
[TBL] [Abstract][Full Text] [Related]
5. Theranostics - a sure cure for cancer after 100 years?
Song Y; Zou J; Castellanos EA; Matsuura N; Ronald JA; Shuhendler A; Weber WA; Gilad AA; Müller C; Witney TH; Chen X
Theranostics; 2024; 14(6):2464-2488. PubMed ID: 38646648
[TBL] [Abstract][Full Text] [Related]
6. Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments.
Farolfi A; Fendler W; Iravani A; Haberkorn U; Hicks R; Herrmann K; Walz J; Fanti S
Eur Urol Oncol; 2019 Mar; 2(2):152-162. PubMed ID: 31017091
[TBL] [Abstract][Full Text] [Related]
7. [PSMA-based theranostics for prostate cancer : From imaging to treatment].
Ilhan H; la Fougère C; Krause BJ
Urologe A; 2020 May; 59(5):617-625. PubMed ID: 32377764
[TBL] [Abstract][Full Text] [Related]
8. Differentiated thyroid cancer theranostics: radioiodine and beyond.
Choudhury PS; Gupta M
Br J Radiol; 2018 Nov; 91(1091):20180136. PubMed ID: 30260232
[TBL] [Abstract][Full Text] [Related]
9. Personalized Medicine Based on Theranostic Radioiodine Molecular Imaging for Differentiated Thyroid Cancer.
Ahn BC
Biomed Res Int; 2016; 2016():1680464. PubMed ID: 27239470
[TBL] [Abstract][Full Text] [Related]
10. Development of Diagnostic and Therapeutic Probes with Controlled Pharmacokinetics for Use in Radiotheranostics.
Ogawa K
Chem Pharm Bull (Tokyo); 2019; 67(9):897-903. PubMed ID: 31474726
[TBL] [Abstract][Full Text] [Related]
11. Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent.
Chatalic KL; Heskamp S; Konijnenberg M; Molkenboer-Kuenen JD; Franssen GM; Clahsen-van Groningen MC; Schottelius M; Wester HJ; van Weerden WM; Boerman OC; de Jong M
Theranostics; 2016; 6(6):849-61. PubMed ID: 27162555
[TBL] [Abstract][Full Text] [Related]
12. Radiotheranostics in oncology: Making precision medicine possible.
Aboagye EO; Barwick TD; Haberkorn U
CA Cancer J Clin; 2023; 73(3):255-274. PubMed ID: 36622841
[TBL] [Abstract][Full Text] [Related]
13. Are nanotheranostics and nanodiagnostics-guided drug delivery stepping stones towards precision medicine?
Blau R; Krivitsky A; Epshtein Y; Satchi-Fainaro R
Drug Resist Updat; 2016 Jul; 27():39-58. PubMed ID: 27449597
[TBL] [Abstract][Full Text] [Related]
14. Scandium and terbium radionuclides for radiotheranostics: current state of development towards clinical application.
Müller C; Domnanich KA; Umbricht CA; van der Meulen NP
Br J Radiol; 2018 Nov; 91(1091):20180074. PubMed ID: 29658792
[TBL] [Abstract][Full Text] [Related]
15. Translating Research for the Radiotheranostics of Nanotargeted
Chang CH; Chang MC; Chang YJ; Chen LC; Lee TW; Ting G
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33918011
[TBL] [Abstract][Full Text] [Related]
16. Big Potential from Small Agents: Nanoparticles for Imaging-Based Companion Diagnostics.
Ehlerding EB; Grodzinski P; Cai W; Liu CH
ACS Nano; 2018 Mar; 12(3):2106-2121. PubMed ID: 29462554
[TBL] [Abstract][Full Text] [Related]
17. Imaging-guided targeted radionuclide tumor therapy: From concept to clinical translation.
Sun J; Huangfu Z; Yang J; Wang G; Hu K; Gao M; Zhong Z
Adv Drug Deliv Rev; 2022 Nov; 190():114538. PubMed ID: 36162696
[TBL] [Abstract][Full Text] [Related]
18. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.
Barrio M; Fendler WP; Czernin J; Herrmann K
Expert Rev Mol Diagn; 2016 Nov; 16(11):1177-1188. PubMed ID: 27679869
[TBL] [Abstract][Full Text] [Related]
19. PSMA expression by microvasculature of thyroid tumors - Potential implications for PSMA theranostics.
Bychkov A; Vutrapongwatana U; Tepmongkol S; Keelawat S
Sci Rep; 2017 Jul; 7(1):5202. PubMed ID: 28701709
[TBL] [Abstract][Full Text] [Related]
20. Theranostics and metabolotheranostics for precision medicine in oncology.
Bhujwalla ZM; Kakkad S; Chen Z; Jin J; Hapuarachchige S; Artemov D; Penet MF
J Magn Reson; 2018 Jun; 291():141-151. PubMed ID: 29705040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
